

Clinical Trials Summary for out of hours Important Reference

Acronym study title	SEATTLE GENETICS EV302
Study Details	An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer.
Principal Investigator PI Sub PI's	Professor Birtle Alison.birtle@lthtr.nhs.uk Telephone (secretary) 01772 524762
Research Nurse Team	Amanda Cook Amanda.cook@lthtr.nhs.uk Telephone 01772 524656 Catherine Walmsley Catherine.walmsley@lthtr.nhs.uk Telephone 01772 528475 Alternative daytime contact Stephanie Cornthwaite (Stephanie.cornthwaite@lthtr.nhs.uk) (01772 523581) Drug therapy
Drug therapy	Arm A Enfortumab Vedotin (Day 1&8) with Pembrolizumab (Day 1). Arm B Gemcitabine (Day 1&8) and Cisplatin/Carboplatin (Day 1).
In the event that a patient calls this hotline for advise	Please treat as per clinical protocols and inform the clinical and research teams. Please liaise with the on-call Consultant or Registrar in the event of an emergency